Topical Tacrolimus: Treatment Failure in a Patient With Alopecia Areata

Thiers, B.H.

doi:10.1001/archderm.136.1.124

Cited by 49 publications

(31 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After 6 months of therapy, there was no hair growth, and the hair loss had progressed to alopecia totalis. 7 This patient's disease was already progressing rapidly when tacrolimus ointment was added, and no current treatment modality alters the course of AA. Five patients with long-standing, treatment-resistant alopecia universalis applied tacrolimus ointment 0.1% once daily for 6 months to a 6 cm 3 6 cm area on the scalp and no hair growth was stimulated.…”

Section: Discussionmentioning

confidence: 99%

Topical tacrolimus in alopecia areata

Price¹,

Willey

Chen

2005

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Topical tacrolimus in alopecia areata

Price¹,

Willey

Chen

2005

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Several case reports have shown treatment failure of tacrolimus in severe AA/AU patients. [61][62][63] It may be that inadequate expression of FKBPs in a subset of AU patients contributes to therapeutic resistance to tacrolimus, revealing a potentially useful marker for therapeutic efficacy. Nevertheless, the limited number of patients within this study limits its direct translation to the bedside.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood gene expression in alopecia areata reveals molecular pathways distinguishing heritability, disease and severity

Coda¹,

Hysa²,

Seiffert-Sinha³

et al. 2010

Genes Immun

View full text Add to dashboard Cite

Alopecia areata (AA) is an autoimmune hair loss disorder in which systemic disturbances have been described, but are poorly understood. To evaluate disease mechanisms, we examined gene expression in the blood of defined clinical subgroups (patchy AA persistent type, AAP, n ¼ 5; alopecia universalis, AU, n ¼ 4) and healthy controls (unaffected relatives, UaR, n ¼ 5; unaffected non-relatives, UaNR, n ¼ 4) using microarrays. Unsupervised hierarchical clustering separates all four patient and control groups, producing three distinct expression patterns reflective of 'inheritance', 'disease' and 'severity' signatures. Functional classification of differentially expressed genes (DEGs) comparing disease (AAP, AU) vs normal (UaR) groups reveals upregulation in immune response, cytokine signaling, signal transduction, cell cycle, proteolysis and cell adhesionrelated genes. Pathway analysis further reveals the activation of several genes related to natural killer-cell cytotoxicity, apoptosis, mitogen activated protein kinase, Wnt signaling and B-and T-cell receptor signaling in AA patients. Finally, 35 genes differentially expressed in AA blood overlap with DEGs previously identified in AA skin lesions. Our results implicate innate and adaptive immune processes while also revealing novel pathways, such as Wnt signaling and apoptosis, relevant to AA pathogenesis. Our data suggest that peripheral blood expression profiles of AA patients likely carry new biomarkers associated with disease susceptibility and expression.

show abstract

“…These agents include imiquimod,100,101 topical calcineurin inhibitors,102–106 botulinum toxin type A,107 topical tri-iodothyronine ointment,108 photodynamic therapy,109–111 and topical 5-fluorounacil 112…”

Section: Other Therapiesmentioning

confidence: 99%

Alopecia areata: a new treatment plan

Alsantali

2011

CCID

View full text Add to dashboard Cite

Many therapeutic modalities have been used to treat alopecia areata, with variable efficacy and safety profiles. Unfortunately, none of these agents is curative or preventive. Also, many of these therapeutic agents have not been subjected to randomized, controlled trials, and, except for topical immunotherapy, there are few published studies on long-term outcomes. The treatment plan is designed according to the patient’s age and extent of disease. In this paper, the therapeutic agents are organized according to their efficacy and safety profiles into first-line, second-line, and third-line options.

show abstract

Topical Tacrolimus: Treatment Failure in a Patient With Alopecia Areata

Cited by 49 publications

References 1 publication

Topical tacrolimus in alopecia areata

Topical tacrolimus in alopecia areata

Peripheral blood gene expression in alopecia areata reveals molecular pathways distinguishing heritability, disease and severity

Alopecia areata: a new treatment plan

Contact Info

Product

Resources

About